Global Neutropenia Treatment Market Report and Forecast 2024-2032

Global Neutropenia Treatment Market Outlook

The global neutropenia treatment market reached a value of about USD 15.69 billion in 2023. The market is projected to grow at a CAGR of 5.3% during the forecast period of 2024-2032 to attain a value of nearly USD 25.09 billion by 2032.  

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Awareness of Neutropenia and Side-effects of Chemotherapy to Augment the Market Growth

In the forecast period, rising awareness of neutropenia and chemotherapy-related side effects, as well as increasing diagnostic technologies, are expected to help accelerate the rise of neutropenia treatment. The significant increase is attributed to a promising therapeutic pipeline that includes around 5 medicines in phase III clinical studies to treat neutropenia. The risk of neutropenia is predicted to increase as the prevalence of leukaemia rises, particularly after treatment.

One of the major drivers of market expansion is new therapies paired with an increase in occurrences of chemotherapy-induced neutropenia. Furthermore, the innovative medication delivery technique improves patient comfort, resulting in increased patient adherence and, as a result, market growth. Furthermore, because cancer is a known cause of neutropenia, the market for neutropenia treatment will benefit from an increase in the number of instances of chemotherapy for cancer treatment.

North America Accounted for the Largest Share While the Asia Pacific is the Fastest Growing Region in the Market

In the worldwide neutropenia treatment industry, North America held the biggest share. North America has had tremendous expansion in the neutropenia treatment industry, and it is likely to dominate the market in the future years. This is due to an increase in the number of cases of leukaemia in the area. In addition, North America is home to many of the market's main participants. Furthermore, the United States dominates the need for neutropenia therapy in North America. The region's dominance is attributable to an increase in demand for febrile neutropenia medications and the implementation of new legislation to promote and manufacture biosimilars. Throughout the forecast period, the Asia Pacific is predicted to develop at the fastest rate in the market. Due to the increasing number of leukaemia cases and patients undergoing first-line chemotherapy treatment in Asia, the neutropenia treatment industry has a lot of room to grow.

Neutropenia Treatment: Market Segmentation

Neutropenia is a rare disease characterised by a sharp drop in neutrophil counts, resulting in weakened immunity. Neutropenia can be caused by a variety of diseases or situations, including chemotherapy for cancer, infections, congenital bone marrow abnormalities, autoimmune disorders, and some medications (drug-induced neutropenia).

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

On the basis of treatment, neutropenia treatment industry is segmented into:

• Colony-stimulating factors 
• Antibiotics
• Antifungals
• Antivirals

Based on the distribution channel, the market is divided into:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

The major regional markets of neutropenia treatment are North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Focus on Research and Development Activities by Companies to Bolster the Market Growth

The neutropenia treatment industry is expected to increase considerably due to major players in the industry supporting research and development as well as public awareness of neutropenia therapy. Companies in this market are focusing on raising knowledge about preventive measures, early diagnosis, and effective treatment of neutropenia as major market tactics. The introduction of small molecules is one of the major technologies gaining traction in the worldwide neutropenia treatment industry. The development of Plinabulin, a tiny chemical with immune-boosting properties created by BeyondSpring Pharmaceuticals, is expected to transform neutropenia treatment. In addition to its immune-boosting properties, Phase II tests have shown that this chemical has even more effective anti-cancer properties. In the neutropenia treatment industry, there is now a significant need for cost-effective medicines. As a result, suppliers are concentrating their efforts on the development of small molecules that have lower processing costs than biologics.

Key Industry Players in the Global Neutropenia Treatment Market

The report gives a detailed analysis of the following key players in the global neutropenia treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

• Amgen, INC.
• Beyondspring, INC.
• Cellerant Therapeutics, Inc.
• Kyowa Kirin 
• Pfizer INC. 
• Novartis Ag 
• Others

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

Key Highlights of the Report